Adjunct Professor of Clinical Medicine
Exercise has been recognized as an essential component of the management of patients with a variety of rheumatic diseases. Previous work has demonstrated that exercise can reduce the pain and disability of osteoarthritis, but compliance with exercise programs can be difficult to maintain. Our preliminary work has suggested that yoga has benefits in osteoarthritis management and we are continuing our investigations into the potential mechanisms that may be involved, including analysis of gait.
1. Kolasinski, S.L. Complementary and Alternative Medicine for the Treatment of Rheumatic Diseases. In Robbins, L., C.S. Burckhardt, M.T. Hannan and R.J. DeHoratius, editors. Clinical Care in Rheumatic Diseases, 2nd Edition. Atlanta: American College of Rheumatology; 2001. p.225-230.
2. Kolasinski, S.L. Complementary and Alternative Therapies for Rheumatic Diseases. Hospital Practice 36:31-39, 2001.
3. Kolasinski, S.L. Yoga for Degenerative Joint Disease. Alternative Medicine Alert 4:28-31, 2001.
4. Kolasinski, S.L. The Use of Alternative Therapies by Patients with Rheumatic Diseases. Journal of Clinical Rheumatology 5:1-2, 1999.
Funding source: Institutional
A Randomized, Double-Blind, Parallel, Multicenter, Placebo-Controlled, Two Year Study to Determine the Efficacy and Safety of Orally Administered 5 and 15 mg/day, and 50 mg/wk Risedronate in Patients with Medial Compartment Knee Osteoarthritis in North America
Osteoarthritis (OA) is increasingly recognized as a disease not only of the joint, but of the surrounding tissues as well, including the subchondral bone. It is hypothesized that increasing the bone density of the subchondral bone may slow biomechanical damage to subchondral bone that is thought to contribute to the progression of OA. This two-year trial is designed to evaluate the role of the bisphosphonate residronate in the prevention of progression of radiographically defined osteoarthritis of the knee.
Funding source: Proctor & Gamble
This observational trial will help assess the clinical status of patients with rheumatoid arthritis as choices are made to alter their treatment regimen.
Funding source: Immunex
This open label trial explores the mechanisms and applicability of B-cell depletion as a potential treatment for systemic lupus erythematosus.
Funding source: NIAID, Genentech/IDEC, Inc.
A Multi-center Double Blind Randomized Study to Evaluate the Efficacy and Safety of Combination Treatment with Anakinra (IL-1a) and PEG related Recombinant Methionyl Human Soluble TNF Receptor Ty11 (PEG STNF-RI) In Subjects with R.A. Receiving Methotrexate
This multi-center trial will evaluate the addition of two biologic agents to the treatment regimen of patients with rheumatoid arthritis who are receiving methotrexate.
Funding source: Amgen
This multi-center trial is designed to evaluate the differences in efficacy and toxicity of the use of oral mycophenolate mofetil with the use of intravenous cyclophosphamide in the management of lupus kidney involvement.
Funding Source: FDA
This multi-center trial will investigate the effect of oral contraceptives and postmenopausal hormone replacement therapy on the disease course of patients with systemic lupus erythematosus.
Funding Source: NIH